Amylyx Pharmaceuticals stock surges after avexitide Phase 3 trial meets endpoints

Shares of Amylyx Pharmaceuticals surged on Tuesday after the biotechnology company reported positive Phase 3 clinical trial results for its experimental drug, avexitide, a potential first treatment for a serious complication of weight-loss surgery.